Key result
SYKT alleviates doxorubicin-induced cardiotoxicity by inhibiting apoptosis via p53 and MAPK pathways.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Should not yet change doxorubicin cardiotoxicity management; leaves open SYKT for further preclinical validation.
Our results indicated that SYKT alleviated DOX-induced cardiotoxicity by inhibiting p53 and MAPK signal pathways' activation-mediated apoptosis, and it might serve as a potential therapeutic agent for DOX-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied this question. SYKT alleviated doxorubicin-induced cardiotoxicity by inhibiting apoptosis mediated by the activation of p53 and MAPK signaling pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: